Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02236975
Recruitment Status : Unknown
Verified August 2016 by Sino Medical Sciences Technology Inc..
Recruitment status was:  Active, not recruiting
First Posted : September 11, 2014
Last Update Posted : August 19, 2016
Sponsor:
Information provided by (Responsible Party):
Sino Medical Sciences Technology Inc.

Brief Summary:

Prospective, multi-center, randomized 1:1, single blind trial using BuMA Supreme versus Resolute Integrity conducted in approximately 14 interventional cardiology centers in The Netherlands, Belgium, Spain and Portugal.

Clinical follow-up will occur at 1, 9 and 12 months post-stent implantation. All patients will undergo repeat angiography at 9 months follow-up. QCA assessment will be performed at baseline (pre- and post-procedure) and at 9 months follow-up.


Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: BuMA Supreme Biodegradable drug coating coronary stent system Device: Resolute Integrity durable polymer stent system Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 168 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Prospective, Multi-center, Randomized First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme eG (Electro Grafting) Based Biodegradable Polymer Sirolimus-eluting Stent and Resolute Integrity Zotarolimus-eluting Durable Polymer Stent in Patients With de Novo Coronary Artery Stenosis.
Study Start Date : April 2015
Estimated Primary Completion Date : November 2016
Estimated Study Completion Date : November 2018

Arm Intervention/treatment
Experimental: BuMA Supreme Biodegradable drug coating coronary stent system
Implant BuMA Supreme stent only
Device: BuMA Supreme Biodegradable drug coating coronary stent system
Active Comparator: Resolute Integrity durable polymer stent system
Implant Resolute stent
Device: Resolute Integrity durable polymer stent system



Primary Outcome Measures :
  1. Late Lumen Loss [ Time Frame: Up to 9 month ]
    The primary endpoint is in-stent Late Lumen Loss (LLL) at 9 months after stent implantation as assessed by off-line QCA.


Secondary Outcome Measures :
  1. Angiographic endpoint [ Time Frame: 9 and 12 month ]
    Acute Lumen Gain (mm);

  2. Angiographic endpoint [ Time Frame: 9 and 12 month ]
    MLD (mm) post procedure and at 9 months;

  3. Angiographic endpoint [ Time Frame: 9 and 12 month ]
    Diameter Stenosis (%) post procedure and at 9 months;

  4. Angiographic endpoint [ Time Frame: 9 and 12 month ]
    Binary Restenosis (DS ≥50%) at 9 months

  5. Clinical endpoint [ Time Frame: 9 and 12 month ]
    Acute success (device and procedural success)

  6. Cinical endpoint [ Time Frame: 9 and 12 month ]
    Device-oriented Composite Endpoints (DoCE) at 1, 9 and 12 months and its individual components. (Device-oriented Composite Endpoint is defined as Cardiac Death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated Target Lesion Revascularization).

  7. Clinical endpoint [ Time Frame: 9 and 12 month ]
    Myocardial infarction (Q-wave, Non q-wave) at all time points.

  8. Clinical endpoint [ Time Frame: 9 and 12 month ]
    Any revascularization at all time points.

  9. Clinical endpoint [ Time Frame: 9 and 12 month ]
    Stent thrombosis according to the ARC definitions up to 12 months follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The subject is at least 18 years of age.
  2. Clinical evidence of ischemic heart disease and/or a positive territorial functional study.
  3. Documented stable angina pectoris (Canadian Cardiovascular Society (CCS) Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia
  4. The patient has a planned intervention of a single de-novo lesion in one or two separate major epicardial territories (LAD, LCX or RCA).
  5. Diameter Stenosis≥50 and<100%.
  6. The visually estimated target lesion must be able to be covered by a single BuMA Supreme stent or a single Resolute Integrity stent (for available sizes refer to tables 1 and 2, page 20 and 21).
  7. The target lesion reference diameter must be visually estimated to be ≥2.5 mm and ≤4.5 mm in diameter.
  8. Written informed consent.
  9. The patient agrees to the follow-up visits including a 9 month angiographic follow-up.
  10. Patient must have completed the follow-up phase of any previous study.

Exclusion Criteria:

  1. Female of child bearing potential (age <50 years and last menstruation within the last 12 months). Subjects with age <50 who underwent tubal ligation, ovariectomy or hysterectomy can be included.
  2. Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of procedure
  3. Patient suffered from stroke/TIA during the last 6 months.
  4. LVEF <30%
  5. Platelet count <100,000 cells/mm3 or >400,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis)
  6. Known renal insufficiency (e.g. serum creatinine >2.5mg/dL, or creatinine clearance ≤30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment).
  7. Patient undergoing planned surgery within 6 months with the necessity to stop DAPT.
  8. Patient requiring oral anticoagulation (Coumadin, Novel Oral Anticoagulant (NOAC))
  9. History of bleeding diathesis or coagulopathy
  10. The patient is a recipient of a heart transplant
  11. Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet medication specified for use in the study, sirolimus, zotarolimus, or cobalt-chromium.
  12. Other medical illness (e.g. cancer, stroke with neurological deficiency) or known history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy
  13. The patient is simultaneously participating in another investigational device or drug study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02236975


Sponsors and Collaborators
Sino Medical Sciences Technology Inc.
Investigators
Layout table for investigator information
Principal Investigator: Clemens von.Birgelen, MD,Phd Medisch Spectrum Twente (MST), Enschede, the Netherlands
Principal Investigator: Manel Sabate, MD,Phd Clinic university hospital Barcelona, Spain
Study Chair: Patrick W.Serruys, MD,Phd Interventional Cardiology, Thorax center, Erasmus MC, Rotterdam

Layout table for additonal information
Responsible Party: Sino Medical Sciences Technology Inc.
ClinicalTrials.gov Identifier: NCT02236975    
Other Study ID Numbers: PIONEER
First Posted: September 11, 2014    Key Record Dates
Last Update Posted: August 19, 2016
Last Verified: August 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Stenosis
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Chlorhexidine
Anti-Infective Agents, Local
Anti-Infective Agents
Disinfectants